Inovio Pharmaceuticals, Inc.
INO
Xếp hạng trong cổ phiếu
#23580
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research,... Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Giá cổ phiếu
$0.9947
Vốn hóa thị trường
$68.73M
Thay đổi (1 ngày)
0.46%
Thay đổi (1 năm)
-87.63%
Quốc gia
US
Giao dịch Inovio Pharmaceuticals, Inc. (INO)
Danh mục
Healthcare
Vốn hóa thị trường của Inovio Pharmaceuticals, Inc.(INO)
Vốn hóa thị trường: $68.73M
Tính đến năm October 2026, Inovio Pharmaceuticals, Inc. có vốn hóa thị trường là $68.73M. Theo dữ liệu của chúng tôi, điều này khiến Inovio Pharmaceuticals, Inc. trở thành công ty có giá trị lớn thứ 23580th trên thế giới theo vốn hóa thị trường. Vốn hóa thị trường là tổng giá trị thị trường của tất cả cổ phiếu đang lưu hành của một công ty niêm yết và thường được sử dụng để đo lường giá trị của công ty đó.
Lịch sử vốn hóa thị trường của Inovio Pharmaceuticals, Inc. từ 2005 đến 2026
INO So với Top 5 phổ biến nhất stocks
